Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules

Inclusion Criteria: * Male or female, non-smoker, ≥18 and ≤75 years of age (Treatment A) or ≥18 and ≤65 years of age (Treatment B), with Body Mass Index (BMI) \>18.5 and \<30.0 kg/m2 * Females of childbearing potential must be willing to use a medically acceptable method of birth control throughout the study * Capable of consent Exclusion Criteria: * Any clinically significant abnormality or abnormal laboratory test results found during medical screening * Positive hepatitis B, hepatitis C, HIV, urine drug screen, urine cotinine test, or alcohol breath test at screening * History of allergic reactions to cyclobenzaprine, any of the formulation component, or other related drugs * Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to the first study drug administration * Positive pregnancy test at screening * Clinically significant electrocardiogram (ECG) abnormalities or vital sign abnormalities at screening * History of significant alcohol or drug abuse within one year prior to screening * Participation in a clinical trial involving the administration of an investigational or marketed drug within 30 days prior to the first dosing or concomitant participation in an investigational study involving no drug administration * Use of medication other than topical products without significant systemic absorption and hormonal contraceptives * Donation of plasma within 7 days prior to dosing, or significant loss of blood within 54 days of dosing. * Abnormal hemoglobin and hematocrit levels at screening * Breast-feeding subject * Presence of dentures, tongue piercings with ongoing use of tongue studs/jewelry, orthodontic braces, or surgical manipulations of the tongue